Overview
Senores Pharmaceuticals Limited (BSE: 544319, NSE: SENORES) disclosed that its Board approved the allotment of 1,170,000 convertible warrants on 28 Mar 2026. The warrants are issued on a preferential basis to promoters and promoter‑group entities.
Financial Impact
- Exercise price per warrant: ₹812 (₹203 paid at allotment, ₹609 payable on conversion).
- Cash received at allotment: ₹23,75,10,000 (≈ ₹23.75 crore).
- Total potential proceeds: ₹95,00,40,000 (≈ ₹95.04 crore) if all warrants are exercised.
- Conversion window: up to 18 months from the allotment date.
The immediate infusion improves liquidity for R&D, working capital, or strategic acquisitions, while the contingent amount offers future financing without additional debt.
Shareholding Impact (assuming full conversion)
| Shareholder | Pre‑issue Shares | Pre‑% | Post‑issue Shares* | Post‑% |
|---|---|---|---|---|
| Swapnil Jatin Shah | 35,53,531 | 7.72% | 37,50,531 | 7.94% |
| Ashokbhai Vijaysinh Barot | 34,44,869 | 7.48% | 35,67,869 | 7.56% |
| Renosen Pharmaceuticals Pvt Ltd | 27,18,719 | 5.90% | 34,57,719 | 7.32% |
| Sangeeta Mukur Barot | 10,42,955 | 2.26% | 11,04,455 | 2.34% |
| Viraj Ashokkumar Barot | 0 | 0.00% | 49,500 | 0.10% |
| Total Promoter Holding | 1,07,60,074 | 23.30% | 1,19,30,074 | 25.26% |
| *Post‑issue figures assume 100% conversion of the warrants. |
The dilution is modest, and promoter control is actually strengthened.
Regulatory Compliance
- Issuance complies with SEBI LODR Regulations (Regulation 30) and SEBI ICDR Regulations (Chapter V).
- Warrants are subject to a lock‑in period as prescribed by SEBI, limiting immediate resale.
- All approvals from BSE and NSE were obtained on 13 Mar 2026.
Risks & Opportunities
Opportunities
- Enhanced capital base for product pipeline expansion, potential acquisitions, or debt reduction.
- Aligns promoter interests with shareholders by providing a structured equity‑raising mechanism.
Risks
- Conversion is not guaranteed; if market conditions are unfavorable, warrants may remain unexercised, limiting the anticipated ₹71.25 crore.
- Lock‑in restrictions could affect liquidity of newly issued shares.
- Potential dilution of existing minority shareholders if conversion occurs.
Conclusion
The preferential warrant issue is a strategic move to raise capital while preserving promoter control. The immediate cash inflow and the option for further funds position Senores Pharmaceuticals for growth, though investors should watch conversion rates and market sentiment.